Background
Name of energy supply system | Energy substrate | Available exercise time | Supply substances and metabolites for ATP recovery |
---|---|---|---|
ATP-CP | ATP | 6 ~ 8 s | CP |
CP | < 10s | CP + ADP → ATP + C | |
Glycolytic system | Glucose | 2 ~ 3 min | Glucose → Lactic acid |
Oxidative system | Glucose | 3 ~ 5 min | Glucose → CO2 + H2O |
Fat | 1 ~ 2 h | Fat → CO2 + H2O |
Sports | Aerobic (%) | Anaerobic (%) | Sports |
---|---|---|---|
Weight lifting, diving, gymnastics | 0 | 100 | 100 m running, Golf and tennis swing |
200 m running, wrestling, Ice hockey | 10 | 90 | Soccer, basketball, baseball, |
20 | 80 | Volleyball, 500 m skiing, 400 m running | |
Tennis, lawn hockey | 30 | 70 | Lacrosse |
800 m running, boxing | 40 | 60 | 200 m swimming, 1500 m skating |
50 | 50 | ||
2000 m rowing | 60 | 40 | 1500 m running |
1500 m running, 400 m swimming | 70 | 30 | 800 m swimming |
3000 m running | 80 | 20 | Trail running |
5000 m running, 10,000 m skating, 10,000 m running, marathon | 90 | 10 | Cross country skiing, jogging |
100 | 0 |
Buffers | Slykes* | % |
---|---|---|
HCO3− | 18.0 | 64 |
Hemoglobin | 8.0 | 29 |
Protein | 1.7 | 6 |
Pi | 0.3 | 1 |
Total | 28.0 | 100 |
Materials and methods
Search strategy
PICOS components | Detail |
---|---|
Participants | Healthy exercise adults |
Intervention | Supplementation with NaHCO3 |
Comparison | Same conditions with placebo or control group |
Outcomes | Changes in some parameters that can express changes in energy metabolism (i.e., HCO3−, pH, BE, BLa, VO2, CO2, PO2 and PCO2) |
Study design | Crossover or counterbalanced double- or single-blind, randomized controlled trials |
Selection of articles: inclusion and exclusion criteria
Items | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | T(s) | % | MQ | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
References | [33] | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 14 | 93.3 | VG |
[29] | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 15 | 100 | E | |
[39] | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 100 | E | |
[28] | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 14 | 93.3 | VG | |
[40] | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 15 | 100 | E | |
[41] | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 14 | 93.3 | VG | |
[42] | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 14 | 93.3 | VG | |
[43] | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 13 | 86.7 | VG | |
[32] | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 14 | 93.3 | VG | |
[31] | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 14 | 93.3 | VG | |
[44] | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 14 | 93.3 | VG | |
[45] | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 14 | 93.3 | VG | |
[46] | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 15 | 100 | E | |
[30] | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 15 | 100 | E | |
[47] | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 15 | 100 | E | |
[48] | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 14 | 93.3 | VG | |
[49] | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 14 | 93.3 | VG | |
T(i) | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 16 | 17 | 17 | 17 | 17 | 6 | 17 | M = 95.28 |
Data extraction and analysis
Results
Study selection and characteristics
References | Study Design | Population characteristics | Intervention | Supplement situation | Experimental design | Physiological Results | Performance results |
---|---|---|---|---|---|---|---|
[33] | Randomized double-blind crossover | 12 M: elite BMX cyclists, age: 19.2 ± 3.4 y, height: 174.2 ± 5.3 cm and BM: 72.4 ± 8.4 kg | 0.3 g•kg− 1 BM of NaHCO3 or 0.045 g•kg−1 BM of NaCI (PLA) | Ingested 90 min before the trial in gelatin capsules once | 3 races of BMX (track length of 400 m) with 15 min interval | ↑HCO3−, ↑pH and ↑BE vs. PLA, (12.95 ± 1.3, 7.2 ± 0.05 and − 12.66 ± 3.13 vs. 11.45 ± 1.3, 7.14 ± 0.05 and − 16.27 ± 3.18), =BLa, =HR, =RPE, =VO2, =VCO2 and = VE vs. PLA | =Time, = Velocity peak (VP) and = Time to VP vs. PLA |
[29] | Double-blind counterbalanced crossover | 18 M: rugby, judo (n = 2) and jiu-jitsu (n = 5), age: 26 ± 5 y; BM: 88.8 ± 6.8 kg; height: 1.78 ± 0.07 m; | 500 mg/kg BM of CL or NaHCO3 or CACO3 (PLA) Divided into four individual doses of 125 mg/kg BM | Last one within 4 h before trial, ingested in gelatin capsules for 5 consecutive days | 4 bouts of the upper body WAnT with 3 min interval | =HCO3−, =pH, =BE, =BLa vs. other conditions | ↑ TWM (2.9%) and ↑ 3rd + 4th of Wingate (5.9%) vs. CL and PLA =1st + 2nd of Wingate |
[39] | Randomized crossover | 10 M: age: 22 ± 4 y, height: 1.77 ± 0.06 m, BM: 76 ± 9 kg. | 0.5 g•kg− 1 BM of NaHCO3 or 0.2 g•kg− 1 BM of NaCI (PLA) Divided into 3 doses | Each dose at 4 h interval on experimental day, ingested as NR once | 2 WAnT with 5 min interval | ↑HCO3−,↑pH and ↑BE vs. PLA (12.7 ± 1.3, 7.22 ± 0.04 and − 13.7 ± 1.8 vs. 9.5 ± 1.7, 7.15 ± 0.05 and − 17.8 ± 2.1), =BLa vs PLA | ↑ Work completed (5 ± 4%) vs. PLA, = Rate of fatigue vs. PLA =PP (↓PLA, −8 ± 8%) |
[28] | Randomized double-blind crossover | 13 M: elite swimmers, age: 20.5 ± 1.4 y, BM: 80.1 ± 8.1 kg, height: 188 ± 8 cm | 0.3 g•kg− 1 BM of NaHCO3 or CACO3 (PLA) | Ingested 60 min before the trial in gelatin capsules once | Two 100 m freestyle sprints with 12 min interval | ↑HCO3−, ↑pH and ↑BE vs. PLA (10.61 ± 3.43, 7.15 ± 0.05 and − 18.68 ± 2.91 vs. 7.77 ± 2.41, 7.05 ± 0.06 and − 22.78 ± 2.21), =BLa vs. PLA | = 1st 100 m swim vs. PLA, ↓ Time of 2nd 100 m swim vs. PLA (1.5 s) |
[40] a | Randomized, double-blind, counterbalanced | 12 M: resistance-trained participants (age: 20.3 ± 2 y, BM:88.3 ± 13.2 kg, height:1.80 ± 0.07 m) | 0.3 g•kg− 1 BM of NaHCO3 or CACO3 (PLA) Divided into 4 equal doses | Each dose consumed at 10 min intervals, 1st dose at 80 min before the trial, ingested in gelatin capsules once | 4 sets of SQ, LP and KE with 120 s interval, 10-12RM per set with 90s interval | ↑HCO3−, ↑pH, ↑BE and ↑BLa vs. PLA (17.86 ± 3.63, 7.35 ± 0.04, − 7.67 ± 4.16 and 17.16 ± 2.09 vs. 14.19 ± 2.62, 7.09 ± 0.03, − 11.5 ± 3.2 and 12.49 ± 2.45) | ↑ Total volume (SQ + LP + KE + PT) vs. PLA (163.7 ± 15.1 vs. 156.7 ± 14.5) |
[41] | Double-blind, counterbalanced | 21 M, age: 25 ± 5 y, BM: 80.7 ± 10.6 kg, height: 1.79 ± 0.06 m | 0.3 g•kg− 1 of BM NaHCO3 or maltodextrin (PLA) | Ingested 0.2 g•kg− 1 BM alongside the breakfast, 0.1 g•kg− 1 BM 2 h before the trial in gelatin capsules once | A habituation trial of the cycle-capacity test to exhaustion at 110% of Wmax | ↑HCO3−, ↑pH, ↑BE and ↑BLa vs. PLA (15.26 ± 2.78, 7.28 ± 0.05, − 9.6 ± 3.38 and 14.5 ± 2.9 vs. 12.82 ± 2.1, 7.23 ± 0.06, − 12.69 ± 2.8 and 12.4 ± 2) | =TWD, except participants who have GI ↑TWD vs. PLA (48.4 ± 9.3 vs. 46.9 ± 9.2) |
[42]a | Randomized double-blind counterbalanced crossover | 20 rowers: age: 23 ± 4 y, height: 1.85 ± 0.08 m, BM: 82.5 ± 8.9 kg, | 0.3 g•kg− 1 BM of NaHCO3 or maltodextrin (PLA) | Ingested 0.2 g•kg− 1 BM 4 h before and 0.1 g•kg− 1 BM 2 h before the trial as NR once | 2000 m rowing-ergometer TTs | ↑HCO3−, ↑pH, ↑BE and ↑BLa vs. PLA (10.56 ± 1.75, 7.18 ± 0.06, − 15.56 ± 2.69 and 16,5 ± 0.9 vs. 9.1 ± 1.71, 7.12 ± 0.07, − 18.13 ± 2.77 and 14.1 ± 0.9) | = Time of 1st and 2nd 500 m, ↓ Time of 3rd and 4th 500 m (0.5 ± 1.2 s and 1.1 ± 1.7 s) |
[43] | Randomized, single-blind, counterbalanced | 14 swimmers (6 M, hight:181.2 ± 7.2 cm; BM: 80.3 ± 11.9 kg, 8F, height: 168.8 ± 5.6 cm; BM: 75.3 ± 10.1 kg) | 0.3 g•kg− 1 BM of NaHCO3 or 0.045 g•kg− 1 BM of NaCI (PLA) | Ingested 2.5 h before the trial as NR once | Completed 8x25m front crawl maximal effort sprints with 5 s interval | ↑HCO3−, ↑pH, ↑BE and ↑BLa vs. PLA (16 ± 0.05, 7.26 ± 0.01, − 11.1 ± 0.08 and 17.69 ± 1.06 vs. 13.8 ± 0.6, 7.2 ± 0.02, − 14.6 ± 1.1 and 14.62 ± 1.25), ↓K+ vs PLA (3.8 ± 0.1 vs. 4.4 ± 0.1), =NA+ | ↓Total swim time (2%) vs. PLA |
[32] | Randomized, double-blind, counterbalance crossover | 10 elite BMX riders, age: 20.7 ± 1.4 y, height: 178.3 ± 2.1 cm and BM: 77.9 ± 2.1 kg, | 0.3 g•kg− 1 BM of NaHCO3 or placebo (PLA) | Ingested 90 min before the trial in gelatin capsules once | 3x30s Wingate tests with 15 min interval | ↑HCO3−, ↑pH and ↑BE vs. PLA (10.17 ± 1.77, 7.22 ± 0.09 and 16.57 ± 3.51 vs. 6.88 ± 2.78, 7.09 ± 0.03 and − 22.49 ± 1.39), =BLa vs. PLA | =PP, = Time to PP, =Mean power, =Fatigue index vs. PLA |
[31] | Randomized double-blind counterbalanced | 11 trained cyclists (10 M and 1F), age: 24.5 ± 2.8 y, height: 1.78 ± 2.7 m and BM: 73.2 ± 3.8 kg | 0.3 g•kg− 1 BM of NaHCO3 or 0.2 g•kg− 1 BM of CaCO3 (PLA) | Ingested 90 min before the trial in gelatin capsules once | 70s supramaximal exercise | ↑HCO3−, ↑pH and ↑BE vs. PLA (19.53 ± 3.98, 7.3 ± 0.03 and − 6.15 ± 3.91 vs. 15.12 ± 3.15, 7.21 ± 0.07 and − 12.67 ± 3.81), =BLa, =VO2, =VCO2, =VE, =PO2, ↑PCO2 vs. PLA (42 ± 2.99 vs. 38.9 ± 3.65) | ↑P50 and ↑Ptot vs. PLA (469.6 ± 28.6 and 564.5 ± 29.5 vs. 448.2 ± 7.7 and 549.5 ± 29.1), =P20 and = Fatigue index vs. PLA |
[44] | Randomized double-blind crossover | 11 M trained cyclists, age: 32 ± 7.2 y; BM: 77.0 ± 9.2 kg | 0.3 g•kg− 1 BM of NaHCO3 or 0.21 g•kg− 1 BM of NaCI (PLA) | Ingested 70-40 min before trial (depending on individual time to peak pH) as NR once | 3 min all-out critical power test | =HCO3−, =H+, =BLa, =PO2 and = PCO2 vs. PLA | ↑TWD (5.5%) and ↑W′ (14%) vs. PLA, =CP vs. PLA |
References | Study Design | Population characteristics | Intervention | Supplement situation | Experimental design | Physiological Results | Performance results |
---|---|---|---|---|---|---|---|
[45] | Randomized single-blind crossover | 6 M: age 24 ± 4 y, height: 1.81 ± 0.10 m, and BM: 73.92 ± 11.46 kg) | 4 mmol•kg− 1 BM of NaHCO3 or NaAc Divided into two equal doses with 45 min interval | Last dose ingested 90 min before trial as NR once | Cycling for 120 min at 119 ± 16 W (~ 50% VO2peak) | ↑blood glucose and ↑Fat oxidation vs. NaAc (3.59 ± 0.45 and 0.11 ± 0.03 vs. 3,21 ± 0.43 and 0.07 ± 0.02) =VO2, =VCO2, =RER, =BLa vs. NaAc | NR |
[46] | Randomized double-blind crossover | 8 M: well-trained cyclists and triathletes, age: 31.4 ± 8.8 y, height: 184.6 ± 6.5 cm, BM: 74.1 ± 7.4 kg, | 0.3 g•kg− 1 BM of NaHCO3 or 0.045 g•kg− 1 BM of NaCI (PLA) | Ingested 90 min before the trial as tablets for 5 consecutive days | Maintain constant-load cycling at ‘CP’ as long as possible | ↑HCO3−, ↑pH and ↑ABE vs. PLA (32.6 ± 2.7, 7.48 ± 0.02 and 8.3 ± 2.3 vs. 26 ± 1.1, 7.43 ± 0.02 and 2.0 ± 09), =Na+, =VO2, =VCO2, =RER and = HR vs. PLA | =CP vs. PLA ↑TTE (23.5%) |
[30] | Double-blind counterbalanced | 11 trained cyclists, age: 35.7 ± 7.1 y, BM: 74.7 ± 10.0 kg, height: 1.75 ± 0.10 m | 0.15 g•kg− 1 BM of NH4CI or 0.03 g•kg− 1 BM of NaHCO3 or 0.15 g•kg− 1 BM of CaCO3 (PLA) | Ingested 100 min before the trial in gelatin capsules once | 4-km cycling | ↑pH vs. PLA (7.3 ± 0.1 vs. 7.2 ± 0.07), =HCO3−, =BE, =BLa, =VO2, =VCO2, =PO2, =PCO2 and = RPE vs. PLA | =PO, =Anaerobic PO and = Aerobic PO vs. PLA |
[47] | Randomized double-blind crossover | 21(16 M, 5F) well-trained cyclists: age: 24 ± 8 y, BMI: 21.3 ± 1.7 kg/m2 | 0.3 g·kg− 1 BM of NaHCO3 or 4 g NaCI (PLA) | Ingested 2 h–1 h before the trial as NR once | 30 min cycling at 95% IAT followed by exercising at 110% IAT until exhaustion | ↑HCO3−, ↑pH and ↑BE vs. PLA (27.6 ± 1.7, 7.45 ± 0.03 and 3.1 ± 1.6 vs. 21.4 ± 2, 7.38 ± 0.03 and − 2.6 ± 1.7), =BLa. =HR, =PCO2, ↓PO2 vs. PLA (83.4 ± 6.5 vs. 88 ± 6.2) | ↑TTE vs. PLA (49.5 ± 11.5 min vs. 45.0 ± 9.5 min) |
[48] | Randomized single-blind crossover | 8F elite hockey players, age: 23 ± 5 y, BM: 62.6 ± 8.4 kg, Height: 1.66 ± 0.05 m | 0.3 g•kg− 1 BM of NaHCO3 or 0.02 g•kg− 1 BM of maltodextrin (PLA) | Ingested 2/3 of NaHCO3 180 min before and 1/3 90 min before the trials in gelatin capsules once | FSHT+ 2 LIST+FSHT+ 10 min recovery+ 2 LIST+FHST, about 75 min total | ↑HCO3−, ↑pH and ↑BE vs. PLA (21.7 ± 2.9, 7.41 ± 0.05 and − 2.3 ± 3.1 vs. 16.8 ± 1.6, 7.34 ± 0.06 and − 7.9 ± 1.8), =Bla, =glucose, =HR vs. PLA | = Performance time and = Sprint time vs. PLA |
[49] | Randomized double-blind crossover | 9 M, college tennis players age 21.8 ± 2.4 y; height 1.73 ± 0.07 m | 0.3 g•kg− 1 BM of NaHCO3 or 0.209 g•kg− 1 BM of NaCI (PLA) | Ingested before 90 min of trial as NR for once | Tennis simulated match, about 50 min | ↑HCO3− and ↑BE vs. PLA (37.98 ± 3.15 and 11.36 ± 3.7 vs. 26.37 ± 3.5 and 0.12 ± 2.15), =pH, =BLa, =hematocrit, =HR and = RPE vs. PLA | = Sport skill performance vs. PLA |